Colchicine clearance is impaired in alcoholic cirrhosis

Jonathan A. Leighton, Michael K. Bay, Alma L. Maldonado, Steven Schenker, Kermit V Speeg

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Colchicine may have benefit in primary biliary cirrhosis and alcoholic liver disease. It is currently used in patients with impaired liver function, yet little is known about its elimination in such patients. Colchicine clearance in the rat is significantly impaired in various models of liver disease. To study this in human beings, colchicine pharmacokinetics were compared in normal subjects and patients with alcoholic cirrhosis. Colchicine clearance was impaired in the cirrhotic patients. Normal subjects had a mean clearance of 10.65 ± 1.82 ml/min ·kg, whereas cirrhotic patients had a mean clearance of 4.22 ± 0.45 ml/min ·kg (p < 0.01). The half-life was 57.4 ± 14.2 min in control subjects vs. 114.4 ± 19.7 min in cirrhotic patients (p = 0.054). Volume of distribution was not different in the two groups (0.718 ± 0.1 L/kg in control subjects; 0.716 ± 0.158 L/kg in cirrhotic patients, p > 0.99). No correlation was seen between colchicine clearance and bilirubin, albumin, prothrombin time or Child-Pugh classification, but this may be the result of the small number of patients studied. Based on the values measured, it is estimated that colchicine steady state would change from an average 1.12 ng/ml in normal individuals to 2.82 ng/ml in the cirrhotic patients if 0.6 mg were taken every 12 hr. It is unknown whether this change would be clinically significant. These data show that cirrhosis impairs colchicine clearance and demonstrates that the liver is a major route of colchicine elimination.

Original languageEnglish (US)
Pages (from-to)1013-1015
Number of pages3
JournalHepatology
Volume14
Issue number6
StatePublished - Dec 1991

Fingerprint

Alcoholic Liver Cirrhosis
Colchicine
Alcoholic Liver Diseases
Biliary Liver Cirrhosis
Liver
Prothrombin Time
Bilirubin
Liver Diseases
Albumins
Fibrosis
Pharmacokinetics

ASJC Scopus subject areas

  • Hepatology

Cite this

Leighton, J. A., Bay, M. K., Maldonado, A. L., Schenker, S., & Speeg, K. V. (1991). Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology, 14(6), 1013-1015.

Colchicine clearance is impaired in alcoholic cirrhosis. / Leighton, Jonathan A.; Bay, Michael K.; Maldonado, Alma L.; Schenker, Steven; Speeg, Kermit V.

In: Hepatology, Vol. 14, No. 6, 12.1991, p. 1013-1015.

Research output: Contribution to journalArticle

Leighton, JA, Bay, MK, Maldonado, AL, Schenker, S & Speeg, KV 1991, 'Colchicine clearance is impaired in alcoholic cirrhosis', Hepatology, vol. 14, no. 6, pp. 1013-1015.
Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology. 1991 Dec;14(6):1013-1015.
Leighton, Jonathan A. ; Bay, Michael K. ; Maldonado, Alma L. ; Schenker, Steven ; Speeg, Kermit V. / Colchicine clearance is impaired in alcoholic cirrhosis. In: Hepatology. 1991 ; Vol. 14, No. 6. pp. 1013-1015.
@article{02e4801b3c3e432db71e33fcbfbcfe99,
title = "Colchicine clearance is impaired in alcoholic cirrhosis",
abstract = "Colchicine may have benefit in primary biliary cirrhosis and alcoholic liver disease. It is currently used in patients with impaired liver function, yet little is known about its elimination in such patients. Colchicine clearance in the rat is significantly impaired in various models of liver disease. To study this in human beings, colchicine pharmacokinetics were compared in normal subjects and patients with alcoholic cirrhosis. Colchicine clearance was impaired in the cirrhotic patients. Normal subjects had a mean clearance of 10.65 ± 1.82 ml/min ·kg, whereas cirrhotic patients had a mean clearance of 4.22 ± 0.45 ml/min ·kg (p < 0.01). The half-life was 57.4 ± 14.2 min in control subjects vs. 114.4 ± 19.7 min in cirrhotic patients (p = 0.054). Volume of distribution was not different in the two groups (0.718 ± 0.1 L/kg in control subjects; 0.716 ± 0.158 L/kg in cirrhotic patients, p > 0.99). No correlation was seen between colchicine clearance and bilirubin, albumin, prothrombin time or Child-Pugh classification, but this may be the result of the small number of patients studied. Based on the values measured, it is estimated that colchicine steady state would change from an average 1.12 ng/ml in normal individuals to 2.82 ng/ml in the cirrhotic patients if 0.6 mg were taken every 12 hr. It is unknown whether this change would be clinically significant. These data show that cirrhosis impairs colchicine clearance and demonstrates that the liver is a major route of colchicine elimination.",
author = "Leighton, {Jonathan A.} and Bay, {Michael K.} and Maldonado, {Alma L.} and Steven Schenker and Speeg, {Kermit V}",
year = "1991",
month = "12",
language = "English (US)",
volume = "14",
pages = "1013--1015",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Colchicine clearance is impaired in alcoholic cirrhosis

AU - Leighton, Jonathan A.

AU - Bay, Michael K.

AU - Maldonado, Alma L.

AU - Schenker, Steven

AU - Speeg, Kermit V

PY - 1991/12

Y1 - 1991/12

N2 - Colchicine may have benefit in primary biliary cirrhosis and alcoholic liver disease. It is currently used in patients with impaired liver function, yet little is known about its elimination in such patients. Colchicine clearance in the rat is significantly impaired in various models of liver disease. To study this in human beings, colchicine pharmacokinetics were compared in normal subjects and patients with alcoholic cirrhosis. Colchicine clearance was impaired in the cirrhotic patients. Normal subjects had a mean clearance of 10.65 ± 1.82 ml/min ·kg, whereas cirrhotic patients had a mean clearance of 4.22 ± 0.45 ml/min ·kg (p < 0.01). The half-life was 57.4 ± 14.2 min in control subjects vs. 114.4 ± 19.7 min in cirrhotic patients (p = 0.054). Volume of distribution was not different in the two groups (0.718 ± 0.1 L/kg in control subjects; 0.716 ± 0.158 L/kg in cirrhotic patients, p > 0.99). No correlation was seen between colchicine clearance and bilirubin, albumin, prothrombin time or Child-Pugh classification, but this may be the result of the small number of patients studied. Based on the values measured, it is estimated that colchicine steady state would change from an average 1.12 ng/ml in normal individuals to 2.82 ng/ml in the cirrhotic patients if 0.6 mg were taken every 12 hr. It is unknown whether this change would be clinically significant. These data show that cirrhosis impairs colchicine clearance and demonstrates that the liver is a major route of colchicine elimination.

AB - Colchicine may have benefit in primary biliary cirrhosis and alcoholic liver disease. It is currently used in patients with impaired liver function, yet little is known about its elimination in such patients. Colchicine clearance in the rat is significantly impaired in various models of liver disease. To study this in human beings, colchicine pharmacokinetics were compared in normal subjects and patients with alcoholic cirrhosis. Colchicine clearance was impaired in the cirrhotic patients. Normal subjects had a mean clearance of 10.65 ± 1.82 ml/min ·kg, whereas cirrhotic patients had a mean clearance of 4.22 ± 0.45 ml/min ·kg (p < 0.01). The half-life was 57.4 ± 14.2 min in control subjects vs. 114.4 ± 19.7 min in cirrhotic patients (p = 0.054). Volume of distribution was not different in the two groups (0.718 ± 0.1 L/kg in control subjects; 0.716 ± 0.158 L/kg in cirrhotic patients, p > 0.99). No correlation was seen between colchicine clearance and bilirubin, albumin, prothrombin time or Child-Pugh classification, but this may be the result of the small number of patients studied. Based on the values measured, it is estimated that colchicine steady state would change from an average 1.12 ng/ml in normal individuals to 2.82 ng/ml in the cirrhotic patients if 0.6 mg were taken every 12 hr. It is unknown whether this change would be clinically significant. These data show that cirrhosis impairs colchicine clearance and demonstrates that the liver is a major route of colchicine elimination.

UR - http://www.scopus.com/inward/record.url?scp=0026352218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026352218&partnerID=8YFLogxK

M3 - Article

C2 - 1959847

AN - SCOPUS:0026352218

VL - 14

SP - 1013

EP - 1015

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -